New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
10:06 EDTACT, TEVA, JBT, PKG, IP, PNFP, CMA, CHK, CFR, PGR, NVO, ADTN, ABC, CCL, BKH, CNP, KMB, SJM, NTI, MUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Actavis (ACT) downgraded to Market Perform from Outperform at Wells Fargo... Adtran (ADTN) downgraded to Neutral from Buy at Mizuho... AmerisourceBergen (ABC) downgraded to Neutral from Buy at UBS... Black Hill (BKH) downgraded to Sector Perform from Outperform at RBC Capital... Carnival (CCL) downgraded to Neutral from Outperform at Exane BNP Paribas... CenterPoint Energy (CNP) downgraded to Underperform from Neutral at Credit Suisse... J.M. Smucker (SJM) downgraded to Sell from Neutral at Goldman... Kimberly Clark (KMB) downgraded to Sell from Neutral at Goldman... Northern Tier (NTI) downgraded to Hold from Buy at Dahlman Rose... Novo Nordisk (NVO) downgraded to Underweight from Neutral at JPMorgan... Progressive (PGR) downgraded to Underweight from Equal Weight at Evercore... Teva (TEVA) downgraded to Market Perform from Outperform at Wells Fargo... JBT Corporation (JBT) downgraded to Neutral from Buy at Sidoti... Packaging Corp. (PKG) downgraded to Underperform from Outperform at CLSA... International Paper (IP) downgraded to Outperform from Buy at CLSA... Pinnacle Financial (PNFP) downgraded to Market Perform from Outperform at Raymond James... Comerica (CMA) downgraded to Underperform from Market Perform at Raymond James... Cullen/Frost (CFR) downgraded to Underperform from Market Perform at Raymond James... Chesapeake (CHK) downgraded to Trim from Hold at Tudor Pickering... Micron (MU) downgraded to Negative from Neutral at Susquehanna.
News For ACT;ADTN;ABC;CCL;BKH;CNP;KMB;SJM;NTI;NVO;PGR;TEVA;JBT;PKG;IP;PNFP;CMA;CHK;CFR;MU From The Last 14 Days
Check below for free stories on ACT;ADTN;ABC;CCL;BKH;CNP;KMB;SJM;NTI;NVO;PGR;TEVA;JBT;PKG;IP;PNFP;CMA;CHK;CFR;MU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 4, 2014
07:34 EDTSJMJ.M. Smucker acquires Sahale Snacks from Palladium Equity Partners
Subscribe for More Information
07:21 EDTTEVAMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
06:53 EDTMUMicron reinstated with a Buy at Deutsche Bank
Deutsche Bank reinstated shares of Micron with a Buy rating saying the company's improved profitability and free cash flow generation are sustainable. The firm has a $40 price target for shares.
06:33 EDTPKGPackaging Corp. initiated with an Outperform at BMO Capital
Subscribe for More Information
06:31 EDTIPInternational Paper initiated with a Market Perform at BMO Capital
Subscribe for More Information
September 3, 2014
16:21 EDTBKHBlack Hills sells generating unit to City Of Gillette for $22M
Subscribe for More Information
10:13 EDTKMBKimberly Clark aims to return 'healthy' amounts of cash to shareholders
Kimberly Clark looks to drive long term growth and strengthen the company despite a "difficult" environment. Says looking to return healthy amounts of cash to shareholders in the form of dividends and share repurchases. Aims to increase dividends roughly in-line with earnings. In terms of advertising, the company plans to increase spending faster than sales growth. Says on-track to spin-off healthcare business and create it into an independent publically traded company in Q4. Says aiming for$1.3B-$1.5B in share repurchases in FY14. Expects continued progress going forward in capital improvement. Aims to drive growth in its international business division. Comments made during Barclays Back-To-School conference.
09:49 EDTKMBKimberly Clark sees FY14 EPS up 4%-7%, consensus $6.09
Subscribe for More Information
09:29 EDTMUMicron, SanDisk have positive read though from Samsung proxy, says Sterne Agee
Subscribe for More Information
07:40 EDTCCLRoyal Caribbean price target raised to $73 from $58 at Jefferies
Subscribe for More Information
05:44 EDTTEVATeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
September 2, 2014
12:47 EDTCMAComerica management to meet with Jefferies
Subscribe for More Information
10:29 EDTNVOHigh option volume stocks
Subscribe for More Information
10:02 EDTPGROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Cabot Oil & Gas (COG) upgraded at Stifel... Century Aluminum (CENX) upgraded to Overweight from Equal Weight at Morgan Stanley... Groupon (GRPN) upgraded at RBC Capital... Hawaiian Electric (HE) upgraded to Neutral from Cautious at ISI Group... Life Time Fitness (LTM) upgraded to Overweight from Neutral at Piper Jaffray... Live Nation (LYV) upgraded to Buy from Neutral at Northcoast... Northrop Grumman (NOC) upgraded at RBC Capital... Panasonic (PCRFY) upgraded to Buy from Sell at CLSA... Progressive (PGR) upgraded at Goldman... RCS Capital (RCAP) upgraded to Buy from Neutral at Citigroup... SandRidge Energy (SD) upgraded at Stifel... Staples (SPLS) upgraded to Outperform from Neutral at Credit Suisse... Statoil (STO) upgraded to Buy from Hold at Deutsche Bank... Tenaris (TS) upgraded to Neutral from Sell at UBS... Tesla (TSLA) upgraded at Stifel... Ultratech (UTEK) upgraded to Outperform from Market Perform at Barrington... Volkswagen (VLKAY) upgraded to Outperform from Neutral at Exane BNP Paribas... Waddell & Reed (WDR) upgraded to Buy from Hold at Jefferies... Willis Group (WSH) upgraded to Outperform from Market Perform at Keefe Bruyette... zulily (ZU) upgraded to Buy from Fair Value at CRT Capital.
09:23 EDTACTActavis announced FDA accepted filing of eluxadoline's NDA
Subscribe for More Information
09:17 EDTJBTJBT awarded $11M contract value from aviation ground services provider
JBT announced that the Company has been awarded a contract valued at over $11M from a U.S.-based aviation ground services provider for the supply of Commander cargo loaders, Tempest aircraft deicing vehicles and Expediter towbarless tractors. The equipment will support the customer's business expansion at a major U.S. international airport. JBT anticipates delivery of the equipment to be completed by year-end 2014.
08:02 EDTTEVATeva reports statistically significant results in reslizumab trial
Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils. In both trials, reslizumab treatment showed both clinically relevant and statistically significant reductions in the frequency of CAE compared to placebo. Reslizumab has also demonstrated a positive effect on lung function and asthma control in the Phase III program . The combination of an effect on clinically important exacerbations and on improvements and preservation of lung function suggest that reslizumab may be a uniquely differentiated treatment for patients with moderate to severe asthma with elevated levels of blood eosinophils. This initial set of results shows the adverse event profile of reslizumab was comparable to placebo in both trials. The incidence of common AEs was consistent with those seen in a moderate to severe asthma population, the most frequent being upper respiratory tract infections, asthma and headache. Further analyses of additional efficacy and safety data are ongoing. These new data are from two global Phase III 12-month, randomized, double-blind, placebo-controlled, parallel-group studies, evaluating the efficacy and safety of intravenously administered reslizumab once every four weeks, compared to placebo in asthma patients that are inadequately controlled by standard of care therapy.
06:37 EDTPGRProgressive upgraded at Goldman
Subscribe for More Information
05:28 EDTPGRProgressive upgraded to Buy from Neutral at Goldman
Subscribe for More Information
05:18 EDTNVONovo Nordisk discontinues activities within inflammatory disorders
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use